Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01180959 · ClinicalTrials.gov registry record · Phase 2

Erlotinib Plus Bevacizumab in Hepatocellular Carcinoma (HCC) as Second-line Therapy

A Phase 2 study of Liver Cancer, sponsored by M.D. Anderson Cancer Center.

Completed
Registry status
Phase 2
Development phase
45
Enrollment target
1
Study location

NCT01180959 is a Phase 2 study of Liver Cancer that has completed, run by M.D. Anderson Cancer Center. The registered enrollment target is 45 participants, below the 447-participant average among 78 other Liver Cancer trials with a reported enrollment target (90% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01180959, a Phase 2 study of Liver Cancer, has completed, sponsored by M.D. Anderson Cancer Center.

COMPLETED
Registry status
Phase 2
Development phase
45 participants
Enrollment target
1
Study location

Study Summary

The goal of this clinical research study is to learn if the combination of AvastinTM (bevacizumab) and Tarceva (erlotinib hydrochloride) can help to control advanced liver cancer. The safety of this drug combination will also be studied.

Conditions Studied

Liver Cancer

Interventions

  • DRUG Bevacizumab
  • DRUG Erlotinib

Study Locations (1)

Texas

  • University of Texas MD Anderson Cancer Center - Houston

Trial Details

FieldValue
Enrollment Target 45 participants
Start Date 2011-04-14
Est. Completion 2021-05-19
Phase Phase 2

Sponsor

M.D. Anderson Cancer Center

2,692 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT01180959

The ClinicalTrials.gov registry entry for NCT01180959 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 45 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 447-participant average among 78 other Liver Cancer trials with a reported enrollment target (90% lower). The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Liver Cancer appearing as the primary indexed condition, and to 2 interventions - of which Bevacizumab is the first listed.

NCT01180959 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.

Frequently Asked Questions

What is clinical trial NCT01180959 about?

NCT01180959 is a clinical study titled "Erlotinib Plus Bevacizumab in Hepatocellular Carcinoma (HCC) as Second-line Therapy". The goal of this clinical research study is to learn if the combination of AvastinTM (bevacizumab) and Tarceva (erlotinib hydrochloride) can help to control advanced liver cancer. The safety of this drug combination will also be studied.

What is the current status of trial NCT01180959?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 45 participants. The study started on 2011-04-14. Estimated completion is 2021-05-19.

What conditions does trial NCT01180959 study?

This clinical trial studies the following conditions: Liver Cancer.

What interventions are being tested in trial NCT01180959?

The interventions under investigation include: Bevacizumab (DRUG), Erlotinib (DRUG).

Who is sponsoring clinical trial NCT01180959?

This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01180959 being conducted?

This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Liver Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Liver Cancer

All registered trials for this condition

Texas

All trials with a study site in Texas

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.